Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

said Mr. David Allan, Chairman and CEO of YM BioSciences. "We look forward to the American Society of Hematology (ASH) meeting being held in early December 2010, where we expect that detailed initial clinical data from the Phase I and early Phase II portion of the study will be presented. More advanced data from the Phase II portion of the study are anticipated in mid-2011. We remain on track to advance CYT387 towards an NDA-enabling study, potentially in the latter half of 2011, and we are also reviewing opportunities for the compound in the numerous other indications in which evidence of activity has been shown with this family of molecules." Highlights from the first quarter:CYT387:

  • Mayo Clinic concluded dose-escalation in the Phase I portion of the Phase I/II clinical trial of CYT387 in patients with myelofibrosis, a chronic debilitating condition where the patient's bone marrow is replaced by scar tissue. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. The Chair of the trial announced that CYT387 showed significant activity in reducing spleen size and controlling constitutional symptoms in these patients. To date, 41 patients have been enrolled into the Phase II tranche bringing the total number in the study to 62. Given the favorable biological activity and safety data, the Company intends to expand enrolment for the trial up to 120 patients and include centers in the US, Canada and Australia, subject to regulatory approval.

  • CYT387 was granted Orphan Drug Designation by the US FDA in September.

  • Preclinical results for CYT387 were presented demonstrating that it possesses an excellent enzymatic potency and selectivity profile which may provide significant clinical advantages. The results were presented at the European School of Haematology International (ESH) International Conference on Myeloproliferative Neoplasms.

  • '/>"/>
    SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... Platelets, the tiny cell fragments whose job it is ... a cell nucleus. But they can "feel" the physical ... have discovered. , Platelets respond to surfaces with greater ... they "turn on" other platelets and other components of ... smarter than we give them credit for, in that ...
    (Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
    (Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years ... suffering, restoring hope an quality of life and contributing ... because of the innovative cellular biomedicines research that made ... , The company was founded in 1994 in ... chief of research, and Topricin inventor), Aurora Paradise (COO) ...
    (Date:9/22/2014)... 2014 Invisible Sentinel Inc., a ... food and beverage industries, announced today that its ... a non-exclusive agreement by Enartis, a global provider ... an Esseco Group company headquartered in Trecate, Italy, ... and other global markets for their own in-winery ...
    Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
    ... Matrox Graphics Inc., the leading,manufacturer of specialized ... Matrox Xenia(TM) Series display controller boards with its,ME/CCL ... first native PCI Express single-slot board with,all-digital, triple-monitor ... configuration. Xenia Series supports resolutions from <1MP to,8MP ...
    ... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today ... presentation of favorable data,generated by scientists at Amgen, ... scheduled presentation by Dr. Paul Pevsner of the,NYU ... in identifying potential protein,biomarkers in colon cancer samples, ...
    ... 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical ... President and Chief Financial Officer,is scheduled to present ... in New York City on Monday, October 13, ... webcast of the presentation will be available at, ...
    Cached Biology Technology:Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors 2Pressure BioSciences, Inc. Provides Corporate Update 2Pressure BioSciences, Inc. Provides Corporate Update 3Pressure BioSciences, Inc. Provides Corporate Update 4Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
    (Date:9/22/2014)... Yale University researchers are studying a potential new treatment ... disease in which scars develop in the lungs and ... mimic, miR-29, which is delivered to lung tissue intravenously. ... it reversed fibrosis after several days. , The ... EMBO Molecular Medicine . , "The mimic, when injected ...
    (Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
    (Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
    Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
    ... single dose of gene-virus combination cured rats of a ... causes the accumulation of bilirubin –which, untreated, results in ... of Medicine in a report in the Proceedings of ... first time this disease (Crigler-Najjar syndrome) has been completely ...
    ... new approach to predict whether a drug in development ... could get antibiotics to market faster and more cheaply, ... scientists worldwide have sounded the alarm: There simply aren’t ... adept at outwitting the traditional antibiotic arsenal. , Yet ...
    ... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
    Cached Biology News:Gene Therapy Cures Inherited Liver Disease In Rats 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
    ...
    Ras-related C3 botulinum toxin substrate 1...
    Human sVCAM-1/CD106 ELI-PAIR Kit...
    HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: